Elite Pharmaceuticals (Elite Pharmaceuticals) EV-to-Revenue : 2.82 (As of May. 03, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Elite Pharmaceuticals's enterprise value is $133.55 Mil. Elite Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $47.32 Mil. Therefore, Elite Pharmaceuticals's EV-to-Revenue for today is 2.82.

The historical rank and industry rank for Elite Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

ELTP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.75 Med: 9.63 Max: 74.55
Current: 2.82

During the past 13 years, the highest EV-to-Revenue of Elite Pharmaceuticals was 74.55. The lowest was 0.75. And the median was 9.63.

ELTP's EV-to-Revenue is ranked worse than
56.78% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.36 vs ELTP: 2.82

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-03), Elite Pharmaceuticals's stock price is $0.1309. Elite Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05. Therefore, Elite Pharmaceuticals's PS Ratio for today is 2.79.

Elite Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Elite Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals EV-to-Revenue Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-Revenue

Get a 7-Day Free Trial

11.12

4.30

2.39

0.92

0.75

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															0.84	0.75	1.06	2.29	3.06

Competitive Comparison of Elite Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elite Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's EV-to-Revenue falls into.

Elite Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Elite Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	133.549	/	47.318
	=	2.82

Elite Pharmaceuticals's current Enterprise Value is $133.55 Mil.
Elite Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.32 Mil.

Elite Pharmaceuticals (OTCPK:ELTP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Elite Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.1309	/	0.047
	=	2.79

Elite Pharmaceuticals's share price for today is $0.1309.
Elite Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

Elite Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Executives

Mark N Pellegrino	officer: CFO, Secretary, Treasurer	165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov	officer: Chief Commercial Officer	165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J	officer: CFO, Secretary, Treasurer	165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman	officer: CFO, Secretary, Treasurer	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer	director	C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel	director	93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc	10 percent owner	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche	officer: Executive VP of Operations	165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine	director, 10 percent owner	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye	director, 10 percent owner, officer: Chief Scientific Officer	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc	10 percent owner	227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc	10 percent owner	227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim	director, 10 percent owner, officer: President & CEO	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647